Conference Proceedings
Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158
D O'Malley, GM Bariani, PA Cassier, A Marabelle, AR Hansen, A De Jesus Acosta, WH Miller, T Safra, A Italiano, L Mileshkin, L Xu, F Jin, K Norwood, M Maio
ANNALS OF ONCOLOGY | ELSEVIER | Published : 2021
Grants
Funding Acknowledgements
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.